| Literature DB >> 18076562 |
Juan Carlos Vega1, Boris Fernando Sanchez, Luz Mery Montero, Rafael Montaña, Mercedes Del Pilar Mahecha, Bladimir Dueñes, Angela Rocío Baron, Richard Reithinger.
Abstract
We calculated ranges for the cost per disability adjusted life year (DALY) averted for cutaneous leishmaniasis (CL) treatment during an ongoing epidemic of CL in Chaparral, Colombia. Using operational clinical and cost data, we calculated that the cost of treating leishmaniasis patients with standard pentavalent antimony was US$345 (95% CI 277-488) per patient treated and cured. The cost per DALY averted per patient cured with antimony was estimated to be approximately US$15 000 (95% CI 12 226-21 532).Entities:
Mesh：
Substances：
Year: 2007 PMID： 18076562 DOI： 10.1111/j.1365-3156.2007.01962.x
Source DB: PubMed Journal: Trop Med Int Health ISSN： 1360-2276 Impact factor: 2.622